Aprogen

Aprogen is a unique biotechnology venture. Based on long-term basic scientific research results, Aprogen has accumulated unique and innovative protein drug development technologies. They have developed the antibody biosimilars for the first time in Korea and have been transferred to other companies. Since then, they have been developing protein and antibody drug design technology, high efficiency cell line manufacturing technology for antibody drug production, mass production technology of antibody drug using bioreactor , Drug efficacy, and pharmacological characterization technology, they now have unparalleled technology and R & D infrastructure to compete with major overseas pharmaceutical companies. Aprogen's bio business strategy is to develop innovative biopharmaceuticals based on global technological competitiveness and to develop biosimilars products with high clinical effectiveness as long-term proven and marketable biosimilars as blockbuster biopharmaceuticals.

show less